2200 POWELL STREET, EMERYVILLE, CA
Announces Closing of Its Acquisition by Ligand
XOMA Royalty Corporation Annual Meeting Approves Director Appointments
XOMA Royalty Corporation Enters Merger Agreement with Ligand Pharmaceuticals
To Acquire Royalty, Further Accelerating Profit Growth and Strengthening Position as a Leading Biopharma Royalty Aggregator
Amended material disclosure
Annual Report to Security Holders
Investor Presentation
Q1
FY 2025
Q3
Q2
FY 2024
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Prospectus Filed Pursuant to Rule 425
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Merger Proxy Statement
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Notification Filed by a National Security Exchange
Amended Schedule 13D - Ownership Report
S-8 POS
Post-Effective Amendment to Registration Statement